Preclinical activity of ORIC-114, a highly selective, brain penetrant, irreversible kinase inhibitor, against atypical mutations in EGFR

被引：0
|
作者：
Junttila, M. R. [1 ]
Warne, R. [1 ]
Repellin, C. [1 ]
Sambucetti, L. [1 ]
Chang, J. [2 ]
Kim, S. [3 ]
Kim, H. Y. [3 ]
Shin, D. G. [3 ]
Park, D. H. [3 ]
Patel, R. [4 ]
Maneval, E. Chow [4 ]
Multani, P. S. [4 ]
Daemen, A. [5 ]
Friedman, L. [6 ]
机构：
[1] ORIC Pharmaceut Inc, Dept Biol, South San Francisco, CA USA
[2] ORIC Pharmaceut Inc, DMPK, South San Francisco, CA USA
[3] Voronoi Inc, Incheon, South Korea
[4] ORIC Pharmaceut Inc, Clin Dev, San Diego, CA USA
[5] ORIC Pharmaceut Inc, Translat Med Dept, South San Francisco, CA USA
[6] ORIC Pharmaceut Inc, Res Dept, South San Francisco, CA USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2378
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1345P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, demonstrates best-in-class properties against Exon 20 insertions and other atypical EGFR mutations
    Junttila, M.
    Repellin, C. E.
    Warne, R.
    Long, J. E.
    Sambucetti, L.
    Ashley, P.
    Andreatta, G.
    Baik, J.
    Salaniwal, S.
    Colas, C.
    Romero, A.
    Soroceanu, L.
    Patel, R.
    Maneval, E. Chow
    Multani, P. S.
    Daemen, A.
    Friedman, L.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S28 - S28
  • [2] ORIC-114, an orally bioavailable, irreversible kinase inhibitor, has superior brain penetrant properties and enhanced potency in preclinical studies of HER2-positive breast cancer
    Junttila, Melissa R.
    Long, Jason E.
    Warne, Robert
    Kim, Sunghwan
    Lee, Younho
    Kim, Hwan
    Kang, Juhee
    Seok, Jiyoon
    Yoo, Jihye
    Lee, Youngyi
    Seo, Dong-Hyuk Seo
    Son, Jung Beom
    Kim, Daekwon
    Choi, Hwan Geun
    Kim, Nam Doo
    Zavorotinskaya, Tatiana
    Chan, Chelsea
    Panuwat, Matthew
    Sun, Jessica
    Chang, Jae H.
    Friedman, Lori S.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [3] ORIC-114, an orally bioavailable, irreversible kinase inhibitor, has superior brain penetration and antitumor activity in subcutaneous and intracranial NSCLC models
    Long, Jason E.
    Kim, Soochan
    Kim, Ha Yeong
    Shin, Dong Guk
    Park, Dong Hyun
    Warne, Robert
    Das, Akash
    Hegde, Ganapati
    Narayanan, Padmini
    Sambucetti, Lidia
    Chan, Brenda
    Chen, Xi
    Chang, Jae H.
    Gibbons, Paul
    Sun, Jessica
    Panuwat, Matthew
    Friedman, Lori S.
    Junttila, Melissa R.
    CANCER RESEARCH, 2022, 82 (12)
  • [4] Furmonertinib is an Oral, Irreversible, Highly BrainPenetrant Pan-EGFR Inhibitor with Activity Against Classical and Atypical EGFR Mutations
    Musib, L.
    Kowanetz, M.
    Li, Q.
    Luo, H.
    Hu, J.
    Lutzker, S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E14 - E15
  • [5] A global phase 1b study of ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, in patients with advanced solid tumors harboring EGFR Exon 20 or HER2 alterations
    Hong, M. H.
    Spira, A. I.
    Lee, K. H.
    Cho, E. K.
    Han, J-Y.
    Shim, B. Y.
    Lee, J-S.
    Kao, S. C-H.
    Kim, S-W.
    Khattak, A.
    Patel, M.
    Xu, R.
    Wang, J.
    Ariazi, E.
    Daemen, A.
    Maneval, E. Chow
    Multani, P. S.
    Patel, R.
    Ahn, M-J.
    ANNALS OF ONCOLOGY, 2023, 34
  • [6] ORIC-114, a brain penetrant, orally bioavailable, irreversible inhibitor selectively targets EGFR and HER2 exon20 insertion mutants and regresses intracranial NSCLC xenograft tumors.
    Junttila, Melissa R.
    Kim, Sunghwan
    Lee, Younho
    Kim, Hwan
    Kang, Juhee
    Seok, Jiyoon
    Yoo, Jihye
    Lee, Youngyi
    Seo, Dong-Hyuk
    Son, Jung Beom
    Kim, Daekwon
    Choi, Hwan Geun
    Kim, Nam Doo
    Das, Akash
    Sutimantanapi, Dena
    Zavorotinskaya, Tatiana
    Chen, Chelsea
    Chang, Jae
    Panuwat, Matthew
    Friedman, Lori
    CANCER RESEARCH, 2021, 81 (13)
  • [7] Discovery of a highly potent and brain penetrant fourth generation EGFR tyrosine kinase inhibitor
    Kumar, Sanjeev
    Wang, Junmei
    Li, Wenqian
    Pan, Weitao
    Wen, Zhiming
    Yu, Kuo-Long
    Zhao, Genshi
    Yin, Tinggui
    CANCER RESEARCH, 2024, 84 (06)
  • [8] Development of a Potent Brain-Penetrant EGFR Tyrosine Kinase Inhibitor against Malignant Brain Tumors
    Tsang, Jonathan E.
    Urner, Lorenz M.
    Kim, Gyudong
    Chow, Kingsley
    Baufeld, Lynn
    Faull, Kym
    Cloughesy, Timothy F.
    Clark, Peter M.
    Jung, Michael E.
    Nathanson, David A.
    ACS MEDICINAL CHEMISTRY LETTERS, 2020, 11 (10): : 1799 - 1809
  • [9] Preclinical Characterization of a Potent, Selective, Brain-Penetrant Inhibitor of Osimertinib-Resistant EGFR Variants
    Amberg-Johnson, K.
    Xu, J.
    Izadi, H.
    Kannan, R.
    Ellery, S.
    Kurhade, S.
    Verras, A.
    Guo, J.
    Jean, B.
    Svensson, M.
    Hsiao, P.
    Evangelista, E.
    Liu, Z.
    Bell, J.
    Futran, A.
    Akinsanya, K.
    Jensen, K. K.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S618 - S619
  • [10] NX-019, a brain penetrant, mutation selective EGFR inhibitor with broad mutant EGFR activity
    Wilson, K.
    Dusek, R.
    Gammon, G.
    ANNALS OF ONCOLOGY, 2022, 33 : S1588 - S1588
12345